13 - Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents

Medecine et Maladies Infectieuses

Volumn 36, Issue 11-12, 2006, Pages 680-689

  Roig, J ^a   Casal, J ^a   Gispert, P ^a   Gea, E ^a  

^a HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

Author keywords

Antibiotherapy; CAP; Intracellular bacteria

Indexed keywords

ANTACID AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; JOSAMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PEPTIDE DEFORMYLASE INHIBITOR; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; SPIRAMYCIN; STREPTOMYCIN; TELITHROMYCIN; TETRACYCLINE; THEOPHYLLINE; UNINDEXED DRUG;

ACHILLES TENDON RUPTURE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FRANCISELLA TULARENSIS; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; LEGIONELLA; LEGIONNAIRE DISEASE; LUNG TOXICITY; MYCOPLASMA PNEUMONIAE; NONHUMAN; ORNITHOSIS; PATHOGENESIS; PHLEBITIS; Q FEVER; RECOMMENDED DRUG DOSE; RICKETTSIA CONORII; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOXYCYCLINE; FLUOROQUINOLONES; HUMANS; KETOLIDES; MACROLIDES; PNEUMONIA, BACTERIAL; Q FEVER;

EID: 33845291923     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2006.07.020     Document Type: Article

References (83)

1. Amsden G.W. Anti-inflammatory effects of macrolides: an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J. Antimicrob. Chemother. 55 (2005) 10-21
2. Mills G.D., Oehley M.R., and Arrol B. Effectiveness of ß-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia: meta-analysis. BMJ 330 7489 (2005) 460
3. Shefet D., Robenshtok E., Paul M., and Leibovici L. Empirical atypical coverage for inpatients with community-acquired penumonia. Arch. Intern. Med. 165 (2005) 1992-2000
4. Roson B., Carratala J., Fernandez-Sabe N., Tubau F., Manresa F., and Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 164 (2004) 502-508
5. Roig J., Sabria M., and Pedro-Botet M.L. Legionella spp.: community-acquired and nosocomial infections. Curr. Opin. Infect. Dis. 16 (2003) 145-151
6. Blasi F. Atypical pathogens and respiratory tract infections. Eur. Resp. J. 24 (2004) 171-181
7. File T.M., and Tan J.S. Chlamydia pneumoniae pneumonia. Semin. Respir. Crit. Care Med. 21 4 (2000) 285-294
8. Chidiac C., and Maulin L. Legionella pneumophila pneumonia: clinical and therapeutic aspects. Med. Mal. Infect. 33 (2003) 549-553
9. Jackson L.A., and Grayston J.T. Chlamydia pneumoniae. In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 933-942
10. McMillan J.A. Mycoplasma pneumoniae. In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 949-953
11. Edelstein P.H. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann. Intern. Med. 129 (1998) 328-330
12. Howden B.P., Stuart R.L., Tallis G., Bailey M., and Johnson P.D. Treatment and outcome of 104 hospitalized patients with Legionnaires' disease. Intern. Med. J. 33 (2003) 484-488
13. Fitzgeorge R.B., Gibson D.H., Jepras R.I., and Baskerville A. Efficacy of imipenem in experimental Legionnaires' disease. Lancet 1 (1985) 633-634
14. Barker J., Brown M.R., Collier P.J., Farrell I., and Gilbert P. Relationship between Legionella pneumophila and Acanthamoeba polyphaga: physiological status and susceptibility to chemical inactivation. Appl. Environ. Microbiol. 58 (1992) 2420-2425
15. Pohlod D.J., Saravolatz L.D., and Somerville M.M. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin. J. Antimicrob. Chemother. 22 Suppl. D (1988) 49-54
16. Rajagopalan-Levasseur P., Dournon E., Dameron G., Vilde J.L., and Pocidalo J.J. Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and oxoflacin against intracellular multiplication of Legionella pneumophila serogroup 1. Antimicrob. Agents Chemother. 34 (1990) 1733-1738
17. Edelstein P.H., Calarco K., and Yasui V.K. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am. Rev. Respir. Dis. 130 (1984) 849-856
18. Ruiz M., Ewig S., Torres A., Arancibia F., Marco F., Mensa J., et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am. J. Respir. Crit. Care Med. 160 (1999) 923-929
19. Roig J., and Rello J. Legionnaires' disease: a rational approach to therapy. JAC 51 (2003) 1119-1129
20. Roig J., and Rello J. Treatment of Legionnaires' disease. In: Cianciotto N.P. (Ed). Legionella: State of the Art 30 Years after its Recognition (2006), ASM Press, Washington, DC [in press]
21. Edelstein P.H. Chemotherapy of Legionnaires' disease with macrolide or quinolone antimicrobial agents. In: Marre R. (Ed). Legionella (2002), ASM Press, Washington, DC 183-188
22. Sabrià M., Pedro-Botet M.L., Gómez J., Roig J., Vilaseca B., Sopena N., et al. Fluoroquinolones versus macrolides in the treatment of Legionnaires'. Dis. Chest 128 (2005) 1401-1405
23. Blázquez R.M., Espinosa F.J., Alemany L., Ramos R.M., Sánchez-Nieto J.M., Segovia M., et al. Antimicrobial chemotherapy for Legionnaires' disease: levofloxacin versus macrolides. Clin. Infect. Dis. 40 (2005) 800-806
24. Mykietiuk A., Carratalà J., Fernández-Sabe N., Dorca J., Verdaguer R., Manresa F., et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin. Infect. Dis. 40 (2005) 794-799
25. Kraus C.N., Zalkikar J., and Powers J.H. Levofloxacin and macrolides for treatment of Legionnaires' disease. Multiple comparisons give few answers. Clin. Infect. Dis. 41 (2005) 416
26. Davis G.S., Winn Jr. W.C., and Beaty H.N. Legionnaires' disease. Infections caused by Legionella pneumophila and Legionella-like organisms. Clin. Chest Med. 2 (1981) 145-166
27. Roig J., Carreres A., and Domingo C. Treatment of Legionnaires' disease. Drugs 46 (1993) 63-79
28. Amsden G.W. Treatment of Legionnaires' disease. Drugs 65 (2005) 605-614
29. Benhamou D., Bru J.P., Chidiac C., Étienne J., Léophonte P., Marty N., et al. Legionnaires' disease: definition, diagnosis and treatment. Med. Mal. Infect. 35 (2005) 1-5
30. Sanchez F., Mensa J., Martinez J.A., Garcia E., Marco F., Gonzalez J., et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?. Clin. Infect. Dis. 36 (2003) 1239-1245
31. Plouffe J.F., Breiman R.F., Fields B.S., Herbert M., Inverso J., Knirsch C., et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin. Infect. Dis. 37 (2003) 1475-1480
32. Baltch A.L., Bopp L.H., Smith R.P., Michelsen P.B., and Ritz W.J. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J. Antimicrob. Chemother. 56 (2005) 104-109
33. Tano E., Cars O., and Lowdin E. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in a vitro kinetic model. J. Antimicrob. Chemother. 56 (2005) 240-242
34. Edelstein P.H., Shinzato T., Doyle E., and Edelstein M.A. In vitro activity of gemifloxacin (SB-265805, LB2034a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 45 (2001) 2204-2209
35. Higa F., Akamine M., Haranaga S., Tohyama M., Shinzato T., Teteyama M., et al. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species. J. Antimicrob. Chemother (2005)
36. Yu V.L., Greenberg R.N., Zadeikis N., Stout J.E., Khashab M.M., Olson W.H., et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 125 (2004) 2135-2139
37. Santos J., Aguilar L., Garcia-Mendez E., Siquier B., Custardoy J., Garcia-Rey C., et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J. Chemother. 15 (2003) 461-465
38. Gibson D.H., Fitzgeorge R.B., and Baskerville A. Antibiotic therapy of experimental airborne Legionnaires' disease. J. Infect. 7 (1983) 210-217
39. Liebers D.M., Baltch A.L., Smith R.P., Hammer M.C., and Conroy J.V. Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. J. Antimicrob. Chemother. 23 (1989) 37-41
40. Barker J.E., and Farrell I.D. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies. J. Antimicrob. Chemother. 26 (1990) 45-53
41. Moffie B.G., and Mouton R.P. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J. Antimicrob. Chemother. 22 (1988) 457-462
42. Rudin J.E., Evans T.L., and Wing E.J. Failure of erythromycin in treatment of Legionella micdadei pneumonia. Am. J. Med. 76 (1984) 318-320
43. Stout J.E., Sens K., Mietzner S., Obman A., and Yu V.L. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int. J. Antimicrob. Agents 25 (2005) 302-307
44. Carbon C., and Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophilla. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 650-652
45. Tremolieres F., Mayaud C., Mouton Y., Weber P., Dellatolas F., Caulin E., et al. Efficacy and safety of pristinamycin versus amoxicillin in community acquired pneumonia in adults. Pathol. Biol. (Paris) 53 (2005) 503-510
46. Edelstein P.H., Hu B., and Edelstein M.A. In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila. Antimicrob. Agents Chemother. 49 (2005) 2533-2535
47. Dunbar L.M., Khashab M.M., Kahn J.B., Zadeikis N., Xiang J.X., and Tennenberg A.M. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 20 4 (2004) 555-563
48. Reilly K.M., Urban M.A., Barreiro T., Betts R.F., and Trawick D.R. Persistent culture-positive Legionella infection in an immunocompromised host. Clin. Infect. Dis. 40 (2005) e87-e89
49. Gacouin A., Le Tulzo Y., Lavoue S., Camus C., Hoff J., Bassen R., et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med. 28 (2002) 686-691
50. Bodi M., Rodriguez A., Solé-Violan J., Gilavert M.C., Garnacho J., Blanquer J., et al. Antibiotic prescription for community-acquired pneumonia in the Intensive Care Unit. Impact of adherence to IDSA guidelines and outcome. Clin. Infect. Dis. 41 (2005) 1709-1716
51. Hubbard R.B., Mathur R.M., and MacFarlaine J.T. Severe community acquired Legionella pneumonia: treatment, complications and outcome. Q. J. Med. 86 (1993) 327-332
52. Martin S.J., Pendland S.L., Chen C., Schreckenberger P., and Danzinger L.H. In vitro synergy of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Antimicrob. Agents Chemother. 40 (1996) 1419-1421
53. Havlichek D., Pohlod D., and Saravolatz L. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. J. Antimicrob. Chemother. 20 (1987) 875-881
54. Critchley I.A., Jones M.E., Heinze P.D., Hubbard D., Engler H.D., Evangelista A.T., et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin. Microbiol. Infect. 8 (2002) 214-221
55. Bébéar C.M., and Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr. Drug Targets Infect. Disord. 5 (2005) 263-271
56. Yoo B.K., Triller D.M., Yong C.S., and Lodise T.P. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann. Pharmacother. 38 (2004) 1226-1235
57. Lonks J.R., and Goldmann D.A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis. 40 (2005) 1657-1664
58. Waites K.B., and Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microb. Rev. 17 (2004) 697-728
59. Rios A.M., Mejias A., Chavez-Bueno S., Fonseca-Aten M., Katz K., Hatfield J., et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob. Agents Chemother. 48 (2004) 2897-2904
60. Rios A.M., Fonseca-Aten M., Mejias A., Chavez-Bueno S., Katz K., Gomez A.M., et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother 49 (2005) 3970-3973
61. Fonseca-Aten M., Salvatore C.M., Mejias A., Rios A.M., Chavez-Bueno S., Katz K., et al. Evaluation of LBM415(NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia. Antimicrob. Agents Chemother. 49 (2005) 4128-4136
62. Talkington D.F., Waites K.B., Schwartz S.B., and Besser R.E. Emerging from obscurity: understanding pulmonary and extrapulmonary syndromes, pathogenesis and epidemiology of human Mycoplasma pneumoniae infections. In: Scheld W.M., Craig W.A., and Hughes J.M. (Eds). Emerging infections 5 (2001), ASM Press, Washington, DC 57-84
63. Kauppinen M.T., Saikku P., Kujala P., Herva E., and Syrjala H. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51 (1996) 185-189
64. Marrie T.J. Coxiella burnetii (Q fever). In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 869-874
65. Raoult D., Mege J.L., and Marrie T.Q. Fever: queries remaining after decades of research. In: Scheld W.M., Craig W.A., and Hughes J.M. (Eds). Emerging infections 5 (2001), ASM Press, Washington, DC 29-56
66. Schlossberg D. Chlamydia psittaci (Psittacosis). In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 939-942
67. Walker D.H., Herrero-Herrero J.L., Ruiz-Beltran R., Bullon-Sopelana A., and Ramos-Hidalgo A. The pathology of fatal Mediterrenean spotted fever. Am. J. Clin. Patol. 87 (1987) 669-672
68. Raoult D., and Maurin M. Rickettsia species. In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 913-921
69. Letaief A.O., Kaabia N., Chakroun M., Khalifa M., Bouzouaia N., and Jemni L. Clinical and laboratory features of murine typhus in central Tunisia: a report of 7 cases. Int. J. Infect. Dis. 9 (2005) 331-334
70. Jacobs R.F. Francisella tularensis (Tularemia). In: Yu V.L., Weber R., and Raoult D. (Eds). Antimicrobial therapy and vaccines (2002), Apple Trees Productions LLC, New York 301-307
71. Evans M.E., Gregory D.W., Schaffner W., and McGee Z.A. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 64 (1985) 251-269
72. Syrjala H., Schildt R., and Raisainene S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularaemia with norfloxacin and ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 68-70
73. Cross J.T., and Jacobs R.F. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin. Infect. Dis. 17 (1993) 976-980
74. Snavely S.R., and Hodges G.R. The neurotoxicity of antibacterial agents. Ann. Intern. Med. 101 (1984) 92-104
75. Celis G., Gea E., Roig J., Latorre J., Martínez J., and Gomez J. Comparative tolerability of intravenous erythromycin and clarithromycin in hospitalised patients with community-acquired pneumonia. Results of a double-blind, randomised, prospective study. Clin. Drug Invest. 22 (2002) 393-398
76. Knowles S.R., Shapiro L., and Shear N.H. Serious adverse reactions induced by minocycline. Report of 13 patients and review of literature. Arch. Dermatol. 132 (1996) 934-939
77. Prabhakar M., and Krahn A.D. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm. 1 (2004) 624-626
78. Sendzik J., Shakibaei M., Schafer-Korting M., and Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 212 (2005) 24-36
79. Blommel A.L., and Lutes R.A. Severe hyperglycemia during renally adjusted gatifloxacin therapy. Ann. Pharmacother. 39 (2005) 1349-1352
80. Jensen C.W., Flechner S.M., Van Buren C.T., Frazier O.H., Cooley D.A., Lorber M.I., et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 43 (1987) 263-270
81. Wynckel A., Toupance O., Melin J.P., David C., Lavaud S., Wong T., et al. Traitement des légionelloses par ofloxacine chez le transplanté rénal. Absence d'interférence avec la ciclosporine A. Presse Med. 20 (1991) 291-293
82. Hooper T.L., Gould F.K., Swinburn C.R., Featherstone G., Odom N.J., Corris P.A., et al. Ciprofloxacin: a preferred treatment for Legionella infections in patients receiving cyclosporin A. J. Antimicrob. Chemother. 22 (1988) 952-953
83. Radandt J.M., Marchbanks C.R., and Dudley M.N. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin. Infect. Dis. 14 (1992) 272-284